Mut. Pharm. Co. v. Bartlett
Headline: Ruling blocks New Hampshire design-defect verdict against a generic drug maker, holding federal law prevents state rules that would force label changes and limits state lawsuits over generic drug warnings.
Holding: The Court held that federal drug law pre-empts New Hampshire design-defect claims that would require a generic manufacturer to change its label, because federal law forbids generic drug companies from unilaterally altering approved warnings.
- Pre-empts state design-defect claims tied to warnings for FDA-approved generics.
- Limits many lawsuits against generic manufacturers over label adequacy.
- Leaves injured patients with fewer state-law remedies against generic makers.
Summary
Background
Karen Bartlett developed a severe, disfiguring skin reaction after taking a generic version of the pain drug sulindac that her pharmacist dispensed. She sued Mutual Pharmaceutical under New Hampshire's design-defect law and a jury awarded her over $21 million. The label at the time warned of severe skin reactions but did not name Stevens-Johnson Syndrome specifically; the FDA later recommended stronger warnings for all NSAIDs.
Reasoning
The central question was whether federal drug law prevents state design-defect claims that in practice require a generic maker to strengthen a drug's warnings. The Court explained that federal law and regulations bar generic manufacturers from independently changing a drug's composition or label, and it relied on PLIVA v. Mensing to say state duties that force such changes are impossible to follow. The Court rejected the idea that a manufacturer can escape the conflict simply by pulling the drug off the market. Because complying with both laws was impossible, the Court held the New Hampshire claim pre-empted and reversed the lower court.
Real world impact
The decision means that New Hampshire-style design-defect claims that turn on warning adequacy are pre-empted for FDA-approved drugs sold across state lines. Generic drug makers cannot be forced by this sort of state claim to change labels they are legally barred from changing. The Court invited Congress or the FDA to resolve the larger policy questions left open.
Dissents or concurrances
Two dissents argued otherwise: Justice Breyer urged attention to the FDA's expertise and said it was not literally impossible to comply, while Justice Sotomayor warned the majority misread the state claim and said the ruling leaves injured patients without remedies.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?